Search
Parecoxib
go.drugbank.com/drugs/DB08439ApprovedInvestigationalParecoxib is a water-soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. … Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx).
Synonyms: N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamideCategories: COX-2 Inhibitors, Cytochrome P-450 SubstratesDimetindene
go.drugbank.com/drugs/DB08801ApprovedInvestigationalDimetindene (Fenistil) is an antihistamine/anticholinergic used orally and locally as an antipruritic.
Categories: Heterocyclic Compounds, 1-RingProducts: Dimestil 1 mg/g Gel, Fenistil 1 mg - DrageesRoxatidine acetate
go.drugbank.com/drugs/DB08806InvestigationalRoxatidine acetate is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit.
Categories: Heterocyclic Compounds, 1-RingProducts: NEOH 2Azilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigationalAzilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. … It is also available in a combination product with [chlorthalidone].
Mixtures: EDARBI CLD®, EDARBI CLD® 40MG/12.5MGCategories: Angiotensin 2 Receptor Blocker, P-glycoprotein inhibitorsTetraethylammonium
go.drugbank.com/drugs/DB08837InvestigationalAs an experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and tetraethylammonium bromide. … The most common use of tetraethylammonium presently is as a pharmacological research agent that blocks selective potassium channels.
Categories: MATE 1 Substrates, MATE 2 SubstratesSerotonin
go.drugbank.com/drugs/DB08839InvestigationalNutraceuticalFor temporary relief of nervousness, anxiety, mood swings, joint pains, weakness, drowsiness, itching and lethargy. Not evaluated by the FDA, homeopathic product.
Synonyms: 3-(2-Aminoethyl)-1H-indol-5-ol, 5-HTInternational brands: 5-HTP, Super 5-HTPEllagic acid
go.drugbank.com/drugs/DB08846InvestigationalEllagic acid is an investigational drug studied for treatment of Follicular Lymphoma (phase 2 trial), protection from brain injury of intrauterine growth restricted babies (phase 1 and 2 trial), improvement … Ellagic acid is present in several fruits such as cranberries, strawberries, raspberries, and pomegranates.
Categories: Cytochrome P-450 CYP2E1 Inhibitors, Heterocyclic Compounds, 1-RingUlipristal
go.drugbank.com/drugs/DB08867ApprovedInvestigationalIt is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. … Ulipristal is currently recommended as first line therapy for emergency contraception, due to improved efficacy and similar side effect profile as compared to the traditional use of levonorgestrel or the
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: ESMYA® 5 MG COMPRIMIDOS, เอสมายาชนิดเม็ด 5 มก.Fingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigational[A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. … Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesProducts: AXIMOD-MS ® 0.5 MG CÁPSULAS, DROPTON®Cabozantinib
go.drugbank.com/drugs/DB08875ApprovedInvestigationalCabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. … It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index